Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes
Phase of Trial: Phase II
Latest Information Update: 04 Nov 2019
Price : $35 *
At a glance
- Drugs T-lymphocyte cell therapy (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine
- Indications Malignant melanoma; Meningioma; Solid tumours
- Focus Therapeutic Use
- 17 Apr 2019 Planned End Date changed from 28 Jul 2018 to 28 Jul 2028.
- 23 Jun 2017 Planned primary completion date changed from 3 Jul 2017 to 5 Jul 2027.
- 05 Oct 2016 Status changed from suspended to recruiting.